Analyst Price Targets — AGIO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 20, 2026 4:07 pm | Emily Bodnar | H.C. Wainwright | $50.00 | $26.93 | TheFly | H.C. Wainwright cuts Agios target on smaller market post Novo data |
| February 12, 2026 4:40 pm | Greg Renza | Truist Financial | $39.00 | $28.42 | StreetInsider | Agios Pharma (AGIO) PT Raised to $39 at Truist Securities |
| December 26, 2025 11:26 am | — | Leerink Partners | $40.00 | $29.17 | TheFly | Agios Pharmaceuticals price target raised to $40 from $34 at Leerink |
| December 24, 2025 5:29 pm | — | H.C. Wainwright | $62.00 | $29.17 | TheFly | Agios Pharmaceuticals price target raised to $62 from $48 at H.C. Wainwright |
| December 24, 2025 4:55 pm | Gregory Renza | Truist Financial | $38.00 | $29.17 | TheFly | Agios Pharmaceuticals price target raised to $38 from $32 at Truist |
| November 24, 2025 12:25 pm | — | Truist Financial | $32.00 | $25.24 | TheFly | Agios Pharmaceuticals initiated with a Buy at Truist |
| November 20, 2025 11:34 am | — | Goldman Sachs | $25.00 | $25.55 | TheFly | Agios Pharmaceuticals price target lowered to $25 from $40 at Goldman Sachs |
| November 20, 2025 11:26 am | — | Leerink Partners | $34.00 | $22.34 | TheFly | Leerink upgrades Agios to Outperform after 51% pullback |
| October 20, 2025 10:42 am | Emily Bodnar | H.C. Wainwright | $56.00 | $42.33 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Agios Pharma (AGIO) |
| May 2, 2025 1:25 pm | Greg Harrison | Scotiabank | $71.00 | $30.10 | TheFly | Agios Pharmaceuticals price target lowered to $71 from $74 at Scotiabank |
Latest News for AGIO
The market is concerned about the diminished market potential for Agios' mitapavit following today's newsflow.
SG Americas Securities LLC raised its position in Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) by 68.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 46,451 shares of the biopharmaceutical company's stock after purchasing an additional 18,801 shares during the quarter.
CAMBRIDGE, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced the company will host a conference call and live webcast on Wednesday, April 29, 2026, at 8:00 a.m.
Agios Pharmaceuticals jumps 14% as it moves toward accelerated FDA approval for mitapivat in sickle cell disease after key regulatory feedback.
NEW YORK, April 1, 2026 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Agios Pharmaceuticals, Inc. ("Agios Pharmaceuticals, Inc.") (NASDAQ: AGIO) concerning possible violations of federal securities laws. On November 19, 2025, Agios reported topline results from its RISE UP Phase 3 trial of Mitapivat in Sickle Cell Disease.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for AGIO.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.